🔬✨ Advocating for Whole-Body Staging in High-Grade Meningiomas: An Open Letter ✨🔬 We’re excited to highlight a compelling open letter from Dr. Ekin Ermiş and colleagues at Bern University Hospital (Insel Gruppe) recently published in the Journal of Nuclear Medicine. This commentary calls for a reevaluation of current practices, proposing the routine use of [68Ga]Ga-DOTATOC PET/CT for whole-body staging in high-grade meningiomas. 🧠📊 🔹 The Case for Change: Current Limitations: Despite their aggressive nature, high-grade meningiomas are typically considered localized, with limited emphasis on identifying extracranial metastases. Clinical Insights: The authors present compelling examples where whole-body [68Ga]Ga-DOTATOC PET/CT identified metastatic disease (e.g., spine, lungs) that had a direct impact on patient management. 🔹 Why It Matters: Management Implications: Accurate staging can guide more personalized treatment strategies, such as radiotherapy for spinal metastases or systemic therapy using [177Lu]Lu-DOTATOC. Future Directions: With advancements in PET/CT technology, the authors advocate for systematic whole-body staging for metastatic risk stratification in high-grade meningiomas. This thought-provoking piece challenges conventional approaches, urging clinicians and researchers to adopt a broader perspective on staging and management of aggressive meningiomas. 👏 Congratulations to Dr. Ermiş, Dr. Nicolas Bachmann, Dr. Katharina Lutz and Dr. Thomas Pykafor sparking this important conversation in the nuclear medicine and oncology communities! 🔗 Read the open letter: https://lnkd.in/e-Ys98D9
